Clinically, personalized monitoring should integrate regional nutritional profiles (e.g., coastal populations with high fish‐derived VA intake; Nicholls et al. 2013) and CRBP‐1 polymorphisms (15% reduced VA metabolism in rs5882‐C allele carriers; Plunkett et al. 2012), effectively preventing fetal growth restriction (34% risk reduction; Leigh and Kaynak 2020) and teratogenic metabolic dysregulation (OR = 0.62, 95% CI: 0.41–0.93; Song et al. 2025). The gene discussed is RBP1; the disease is fetal growth restriction.